Table. Characteristics of the Comparative Effectiveness Analysis Cohorts of Standard-Interval vs Extended-Interval Dosing of Pembrolizumab.
| Characteristic | No. (%) | P value for differencesa | ||||
|---|---|---|---|---|---|---|
| Standard interval | Standard interval to extended interval | Pooled standard interval | Extended interval | Cohort | ||
| All-diseases cohort | ||||||
| No. | 534 | 142 | 676 | 159 | 835 | |
| Age, mean (SD) | 70.8 (8.5) | 71.1 (10.0) | 70.9 (8.8) | 70.9 (8.5) | 70.9 (8.7) | .99 |
| Male sex | 514 (96.3) | 139 (97.9) | 653 (96.7) | 156 (98.1) | 809 (96.9) | .32 |
| Noncancer CCI | 2.3 (2.0) | 2.2 (1.9) | 2.3 (2.0) | 2.1 (1.8) | 2.3 (2.0) | .25 |
| Primary site | ||||||
| Lung | 238 (44.6) | 59 (41.5) | 297 (43.9) | 76 (47.8) | 373 (44.7) | .38 |
| Bladder | 82 (15.4) | 27 (19.0) | 109 (16.1) | 28 (17.6) | 137 (16.4) | .65 |
| Kidney | 64 (12.0) | 19 (13.4) | 83 (12.3) | 11 (6.9) | 94 (11.3) | .05 |
| Head and neck | 58 (10.9) | 16 (11.3) | 74 (10.9) | 20 (12.6) | 94 (11.3) | .56 |
| Melanoma | 44 (8.2) | 19 (13.4) | 63 (9.3) | 13 (8.2) | 76 (9.1) | .65 |
| Gastroesophageal | 54 (10.1) | 8 (5.6) | 62 (9.2) | 8 (5.0) | 70 (8.4) | .09 |
| Colorectal | 25 (4.7) | 10 (7.0) | 35 (5.2) | 10 (6.3) | 45 (5.4) | .58 |
| Hepatocellular | 26 (4.9) | 4 (2.8) | 30 (4.4) | 9 (5.7) | 39 (4.7) | .51 |
| NSCLC cohort | ||||||
| Age, mean (SD) | 71.8 (7.2) | 71.5 (9.2) | 71.8 (7.5) | 71.2 (6.6) | 71.6 (7.3) | .59 |
| Male sex | 144 (95.4) | 30 (100) | 174 (96.1) | 51 (96.2) | 225 (96.2) | .98 |
| Noncancer CCI | 2.5 (1.9) | 2.3 (1.7) | 2.4 (1.9) | 2.0 (1.7) | 2.3 (1.9) | .12 |
Abbreviations: CCI, Charlson Comorbidity Index; NSCLC, non−small cell lung cancer.
a
Tests of statistical significance compared pooled standard- and extended-interval cohorts. Summary statistics of patients included in the all-diseases and NSCLC cohorts. No meaningful between-groups differences were identified.